skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients

Original Research

(2027) Views  (725) Full article downloads

Authors: Paraskevi F Katsakiori, Eirini P Papapetrou, Dimitrios S Goumenos, et al

Published Date June 2010 Volume 2010:6 Pages 265 - 269
DOI: http://dx.doi.org/10.2147/TCRM.S11501

Paraskevi F Katsakiori1, Eirini P Papapetrou2, Dimitrios S Goumenos3, George C Nikiforidis4, Christodoulos S Flordellis1

Departments of 1Pharmacology, 3Internal Medicine-Nephrology, 4Medical Physics, School of Medicine, University of Patras, Rion, Greece; 2Center for Cell Engineering, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Background: As proton pump inhibitors share CYP3A4 enzyme with tacrolimus for their hepatic elimination, they potentially affect its pharmacokinetics, most prominently in patients with CYP2C19 or CYP3A5 gene mutations. Our aim was to investigate the impact of omeprazole on tacrolimus pharmacokinetics in CYP3A5 non-expressors, kidney transplant recipients.

Methods: Twelve patients (five males/seven females) were observed for 175 ± 92.05 days. Omeprazole (20 mg pos) was administrated for 75.83 ± 45.17 days. Immunosuppressant regimen consisted of tacrolimus (n = 12), methylprednisolone (n = 10), mycophenolate mofetil (n = 11), azathioprine (n = 1), and everolimus (n = 2). Patient’s body weight, coadministered drugs, and tacrolimus trough levels were monitored. Aspartate and alanine aminotransferase, γ-glutamyltransferase, and bilirubin were used for evaluating hepatic function. Tacrolimus kinetics were estimated with daily dose, concentration, dose adjusted concentration, and volume of distribution with and without coadministration of omeprazole. CYP3A5 genotyping was performed with PCR followed by restriction fragment length polymorphism analysis. Statistical analysis was performed with Prism 4 software (GraphPad Software, Inc).

Results: No statistically significant difference was observed in tacrolimus kinetics and hepatic function during coadministration of omeprazole.

Conclusion: Our results let us propose that there is no need for more frequent therapeutic drug monitoring of tacrolimus when coadministrated with omeprazole in CYP3A5 nonexpressors, though prospective studies with more patients and longer observation period are needed to confirm these findings.

Keywords: CYP3A5, omeprazole, renal transplantation, tacrolimus








Readers of this article also read:

Current trends in the treatment of polycystic ovary syndrome with desire for children
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Update on the management of attention-deficit/hyperactivity disorder in children and adults: patient  onsiderations and the role of lisdexamfetamine
Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
Review of mifamurtide in the treatment of patients with osteosarcoma
Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazole
Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases
Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Clinical utility of esomeprazole for treatment of gastroesophageal reflux disease in pediatric and adolescent patients